Bristol Myers Squibb and Amgen: Strong 10-Year Investment Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Bristol Myers Product Line: Despite facing challenges from patent cliffs, Bristol Myers Squibb's stock has underperformed over the past 12 months; however, its deep product lineup, especially in oncology, and new approvals like the subcutaneous formulation of Opdivo will help fend off competition, thereby maintaining revenue and earnings growth.
- Innovative Drug Development: Bristol Myers is developing BMS-986446 for Alzheimer's disease, which has received Fast Track Designation from the FDA; although developing therapies for Alzheimer's has historically been challenging, its potential could provide new revenue streams and further solidify the company's dividend program.
- Amgen's Market Performance: Amgen performed well in 2025 but faces the impact of patent cliffs; nevertheless, its growth drivers, including asthma treatment Tezspire and Tepezza for thyroid eye disease, continue to expand, which is expected to drive future sales growth.
- Robust Dividend Policy: Amgen boasts a dividend yield exceeding 3% and has increased its dividend annually since its initiation in 2011, indicating the safety of its dividend policy, making it an ideal choice for income-seeking investors.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 330.030
Low
272.00
Averages
345.87
High
425.00
Current: 330.030
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
